News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
511,016 Results
Type
Article (47595)
Company Profile (237)
Press Release (463184)
Section
Business (150386)
Career Advice (1496)
Deals (24889)
Drug Delivery (85)
Drug Development (65913)
Employer Resources (151)
FDA (10126)
Job Trends (11149)
News (251505)
Policy (20077)
Tag
Academia (2380)
Africa (639)
Alliances (37701)
Alzheimer's disease (1009)
Antibody-drug conjugate (ADC) (58)
Approvals (10067)
Arizona (104)
Artificial intelligence (68)
Asia (29945)
Australia (5472)
Bankruptcy (175)
Best Places to Work (8662)
Biotechnology (171)
C2C Services and Suppliers (48163)
California (1499)
Canada (703)
Cancer (467)
Career advice (1260)
CAR-T (54)
Cell therapy (138)
China (114)
Clinical research (50247)
Collaboration (122)
Compensation (53)
Connecticut (57)
COVID-19 (2016)
Cystic fibrosis (64)
Data (250)
Diabetes (60)
Diagnostics (4775)
Earnings (54058)
Employer resources (132)
Europe (69477)
Events (81634)
Executive appointments (127)
FDA (10274)
Florida (190)
Funding (108)
Gene therapy (94)
Georgia (52)
GLP-1 (439)
Government (2650)
Healthcare (13096)
Hotbed/Location (343327)
Illinois (156)
Indiana (111)
Infectious disease (2037)
Inflammatory bowel disease (87)
Interviews (236)
IPO (11826)
Job creations (2615)
Job search strategy (1127)
Kansas (55)
Layoffs (312)
Legal (4208)
Liver cancer (51)
Lung cancer (118)
Manufacturing (68)
Maryland (242)
Massachusetts (1189)
Medical device (7541)
Medtech (7546)
Mergers & acquisitions (13040)
Metabolic disorders (197)
Michigan (118)
Minnesota (150)
Neuroscience (1139)
New Jersey (450)
New York (507)
NextGen Class of 2024 (4530)
Non-profit (3306)
North Carolina (488)
Northern California (683)
Obesity (122)
Ohio (84)
Opinion (156)
Patents (53)
Pennsylvania (388)
People (47185)
Phase I (16420)
Phase II (22286)
Phase III (16374)
Pipeline (100)
Postmarket research (1808)
Preclinical (7776)
Press Release (72)
Rare diseases (117)
Real estate (4590)
Recruiting (57)
Regulatory (13911)
Research institute (2225)
Resumes & cover letters (225)
South America (833)
Southern California (597)
Startups (3070)
Texas (182)
United States (6516)
Vaccines (354)
Washington State (227)
Weight loss (106)
Date
Today (145)
Last 7 days (554)
Last 30 days (1734)
Last 365 days (30924)
2024 (21384)
2023 (33015)
2022 (41736)
2021 (44904)
2020 (41355)
2019 (33813)
2018 (25562)
2017 (25441)
2016 (24443)
2015 (29527)
2014 (23364)
2013 (19968)
2012 (19712)
2011 (20101)
2010 (19000)
511,016 Results for "cel sci corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments.
May 16, 2024
·
7 min read
Business
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
CEL-SCI Corporation announced Dr. Giovanni Selvaggi, an oncology key opinion leader instrumental in successfully bringing several drugs to market has joined CEL-SCI as a Clinical Advisor.
June 6, 2024
·
7 min read
Business
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
CEL-SCI Corporation announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy.
April 23, 2024
·
4 min read
Business
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
CEL-SCI Corporation reported financial results for the quarter ended December 31, 2023, as well as key recent clinical and corporate developments.
February 15, 2024
·
7 min read
BioCapital
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
CEL-SCI Corporation (NYSE American: CVM) today announced the peer reviewed scientific journal Frontiers in Immunology published an article regarding CEL-SCI’s Ligand Epitope Antigen Presentation System (LEAPS).
March 19, 2024
·
5 min read
Drug Development
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
CEL-SCI Corporation (NYSE American: CVM) today announced a significantly positive outcome from its recent meeting with the U.S. Food and Drug Administration (FDA) regarding the path to approval for its first-line investigational cancer immunotherapy Multikine* (Leukocyte Interleukin, Injection).
May 8, 2024
·
7 min read
BioCapital
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
CEL-SCI Corporation announced the Company’s Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled “Neoadjuvant Immunotherapy for Head and Neck Cancer: Low Tumor PD-L1 Expression - IT-MATTERS – RCT” at the International Drug Discovery Science & Technology 20th Annual Congress in Budapest, Hungary on Tuesday, June 18, 2024.
June 18, 2024
·
5 min read
Business
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate developments.
December 22, 2023
·
8 min read
Deals
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 3,875,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $7.75 million, before deducting underwriting discounts and offering expenses.
February 13, 2024
·
4 min read
BioCapital
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
CEL-SCI Corporation (NYSE American: CVM) today announced that the European Medicines Agency (EMA) Paediatric Committee granted CEL-SCI a product-specific waiver of strict requirements for commercialization of cancer drugs in the European Union (EU).
January 31, 2024
·
12 min read
1 of 51,102
Next